Posted on 02/07/2010 in Medical Company Restructures Alcon has announced an extraordinary general meeting of shareholders next month in order to vote on the conditional election of a number of new directors.
Norman Walker and Dr Enrico Vanni are standing for election until 2011, while Dr Urs Baerlocher and Dr Jacques Seydoux's proposed terms will last until 2013.
Dr Paul Choffat will also be standing at the meeting, with his term lasting until 2012.
All five of the candidates have been proposed by pharmaceutical company Novartis ahead of its planned move to purchase shares in Alcon that are currently owned by Nestle.
The directors would only take their places on the board should Novartis' buyout go ahead, at which point they will replace Nestle-nominated Alcon directors.
Alcon confirmed that this will be the only item of business set to be discussed at the meeting, which takes place on August 16th 2010.
According to Alcon's most recent financial report, published in April 2010, the eye care company experienced a solid performance in the first quarter of this year, seeing a 15.3 per cent year-on-year increase in global sales.Other news stories from 02/07/2010
Read more in the Zenopa News Archive
How this news is generated
|
